Cost-Benefit Analysis of Sumatriptan Tablets versus Usual Therapy for Treatment of Migraine

We performed a systematic assessment of the costs and benefits of sumatriptan and usual therapy for migraine from society's perspective. A decision tree was constructed with probability estimates based on data from an open‐label clinical trial assessing the economic and human impacts of sumatri...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2000-11, Vol.20 (11), p.1356-1364
Main Authors: Biddle, Andrea K., Shih, Ya-Chen Tina, Kwong, W. Jacqueline
Format: Article
Language:English
Subjects:
Absenteeism
Biological and medical sciences
Cardiovascular system
Cost of Illness
Cost-Benefit Analysis
Decision Trees
Double-Blind Method
Female
Humans
Medical sciences
Migraine Disorders - drug therapy
Migraine Disorders - economics
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Serotonin Receptor Agonists - economics
Serotonin Receptor Agonists - therapeutic use
Sumatriptan - economics
Sumatriptan - therapeutic use
Time Factors
Vasodilator agents. Cerebral vasodilators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We performed a systematic assessment of the costs and benefits of sumatriptan and usual therapy for migraine from society's perspective. A decision tree was constructed with probability estimates based on data from an open‐label clinical trial assessing the economic and human impacts of sumatriptan and usual therapy on nursing personnel. Direct medical care costs including costs for drug, physician, and emergency room visits were considered. Benefits were estimated using the human capital approach based on the national average of weekly earnings and productivity loss estimated from a migraine clinical trial. The net benefits of sumatriptan and usual therapy for the treatment of a single migraine attack were estimated to be $50 and $20, respectively. The annual incremental net benefit of sumatriptan over usual therapy was estimated to be $114–540/patient. The price difference was offset by benefits of sumatriptan in reducing use of health care resources and productivity loss.
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.20.17.1356.34890